194 related articles for article (PubMed ID: 20549827)
21. Effect of Aromatase Inhibitor Therapy on Sleep and Activity Patterns in Early-stage Breast Cancer.
Bhave MA; Speth KA; Kidwell KM; Lyden A; Alsamarraie C; Murphy SL; Henry NL
Clin Breast Cancer; 2018 Apr; 18(2):168-174.e2. PubMed ID: 29361424
[TBL] [Abstract][Full Text] [Related]
22. Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms.
Hertz DL; Douglas JA; Miller RM; Kidwell KM; Gersch CL; Desta Z; Storniolo AM; Stearns V; Skaar TC; Hayes DF; Henry NL; Rae JM
Support Care Cancer; 2022 Oct; 30(10):8059-8067. PubMed ID: 35776183
[TBL] [Abstract][Full Text] [Related]
23. Hypovitaminosis D is a predictor of aromatase inhibitor musculoskeletal symptoms.
Singer O; Cigler T; Moore AB; Levine AB; Do HT; Mandl LA
Breast J; 2014; 20(2):174-9. PubMed ID: 24467395
[TBL] [Abstract][Full Text] [Related]
24. Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort.
Castel LD; Hartmann KE; Mayer IA; Saville BR; Alvarez J; Boomershine CS; Abramson VG; Chakravarthy AB; Friedman DL; Cella DF
Cancer; 2013 Jul; 119(13):2375-82. PubMed ID: 23575918
[TBL] [Abstract][Full Text] [Related]
25. Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study.
Henry NL; Pchejetski D; A'Hern R; Nguyen AT; Charles P; Waxman J; Li L; Storniolo AM; Hayes DF; Flockhart DA; Stearns V; Stebbing J
Br J Cancer; 2010 Jul; 103(3):291-6. PubMed ID: 20606683
[TBL] [Abstract][Full Text] [Related]
26. Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer.
Hertz DL; Smith KL; Zong Y; Gersch CL; Pesch AM; Lehman J; Blackford AL; Henry NL; Kidwell KM; Rae JM; Stearns V
Front Genet; 2021; 12():662734. PubMed ID: 34211496
[TBL] [Abstract][Full Text] [Related]
27. Single arm phase II study of oral vitamin B12 for the treatment of musculoskeletal symptoms associated with aromatase inhibitors in women with early stage breast cancer.
Campbell A; Heydarian R; Ochoa C; Dwivedi AK; Nahleh ZA
Breast J; 2018 May; 24(3):260-268. PubMed ID: 29442401
[TBL] [Abstract][Full Text] [Related]
28. Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms?
Muslimani AA; Spiro TP; Chaudhry AA; Taylor HC; Jaiyesimi I; Daw HA
Clin Breast Cancer; 2009 Feb; 9(1):34-8. PubMed ID: 19299238
[TBL] [Abstract][Full Text] [Related]
29. Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors.
Kadakia KC; Kidwell KM; Seewald NJ; Snyder CF; Storniolo AM; Otte JL; Flockhart DA; Hayes DF; Stearns V; Henry NL
Breast Cancer Res Treat; 2017 Jul; 164(2):411-419. PubMed ID: 28451964
[TBL] [Abstract][Full Text] [Related]
30. Aromatase inhibitor-associated arthralgia syndrome.
Burstein HJ
Breast; 2007 Jun; 16(3):223-34. PubMed ID: 17368903
[TBL] [Abstract][Full Text] [Related]
31. Attempted replication of pharmacogenetic association of variants in PPP1R14C and CCDC148 with aromatase inhibitor-induced musculoskeletal symptoms.
Liang Y; Gersch CL; Lehman J; Henry NL; Smith KL; Rae JM; Stearns V; Hertz DL
Pharmacogenet Genomics; 2024 Jun; 34(4):126-129. PubMed ID: 38359166
[TBL] [Abstract][Full Text] [Related]
32. The Role of Diuretics in Treatment of Aromatase Inhibitors Induced Musculoskeletal Symptoms in Women with Non Metastatic Breast Cancer.
Alhanafy AM; Labeeb A; Khalil A
Asian Pac J Cancer Prev; 2018 Dec; 19(12):3525-3531. PubMed ID: 30583679
[TBL] [Abstract][Full Text] [Related]
33. Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients.
Borrie AE; Rose FA; Choi YH; Perera FE; Read N; Sexton T; Lock M; Vandenberg TA; Hahn K; Younus J; Logan D; Potvin K; Yaremko B; Yu E; Lenehan J; Welch S; Teft WA; Kim RB
Breast Cancer Res Treat; 2020 Sep; 183(2):365-372. PubMed ID: 32632513
[TBL] [Abstract][Full Text] [Related]
34. Associations Between Patient and Anthropometric Characteristics and Aromatase Inhibitor Discontinuation.
Henry NL; Speth K; Lintermans A; Kidwell KM; Carlson R; Hayes DF; Neven P
Clin Breast Cancer; 2017 Aug; 17(5):350-355.e4. PubMed ID: 28365336
[TBL] [Abstract][Full Text] [Related]
35. Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer.
Kadakia KC; Snyder CF; Kidwell KM; Seewald NJ; Flockhart DA; Skaar TC; Desta Z; Rae JM; Otte JL; Carpenter JS; Storniolo AM; Hayes DF; Stearns V; Henry NL
Oncologist; 2016 May; 21(5):539-46. PubMed ID: 27009936
[TBL] [Abstract][Full Text] [Related]
36. Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor-related arthralgia.
Dizdar O; Ozçakar L; Malas FU; Harputluoglu H; Bulut N; Aksoy S; Ozisik Y; Altundag K
J Clin Oncol; 2009 Oct; 27(30):4955-60. PubMed ID: 19752344
[TBL] [Abstract][Full Text] [Related]
37. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study.
Mieog JS; Morden JP; Bliss JM; Coombes RC; van de Velde CJ;
Lancet Oncol; 2012 Apr; 13(4):420-32. PubMed ID: 22265698
[TBL] [Abstract][Full Text] [Related]
38. A Cohort Study to Evaluate Genetic Predictors for Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS): Results from ECOG-ACRIN E1Z11.
Stearns V; Jegede OA; Chang VT; Skaar TC; Berenberg JL; Nand R; Shafqat A; Jacobs NL; Luginbuhl W; Gilman P; Benson AB; Goodman JR; Buchschacher GL; Henry NL; Loprinzi CL; Flynn PJ; Mitchell EP; Fisch MJ; Sparano JA; Wagner LI
Clin Cancer Res; 2024 Apr; ():. PubMed ID: 38640040
[TBL] [Abstract][Full Text] [Related]
39. Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients.
Hack CC; Häberle L; Brucker SY; Janni W; Volz B; Loehberg CR; Hartkopf AD; Walter CB; Baake G; Fridman A; Malter W; Wuerstlein R; Harbeck N; Hoffmann O; Kuemmel S; Martin B; Thomssen C; Graf H; Wolf C; Lux MP; Bayer CM; Rauh C; Almstedt K; Gass P; Heindl F; Brodkorb T; Willer L; Lindner C; Kolberg HC; Krabisch P; Weigel M; Steinfeld-Birg D; Kohls A; Brucker C; Schulz V; Fischer G; Pelzer V; Rack B; Beckmann MW; Fehm T; Rody A; Maass N; Hein A; Fasching PA; Nabieva N
Breast; 2020 Apr; 50():11-18. PubMed ID: 31958661
[TBL] [Abstract][Full Text] [Related]
40. Pharmacology of arthralgia with estrogen deprivation.
Lintermans A; Neven P
Steroids; 2011 Jul; 76(8):781-5. PubMed ID: 21377484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
